Additive effects of nicorandil on coronary blood flow during continuous administration of nitroglycerin
Atsunori Okamura, MD*,
Hiromi Rakugi, MD*,
Mitsuru Ohishi, MD*,
Yoshihiro Yanagitani, MD*,
Masumi Shimizu, MD*,
Tadahiko Nishii, MD ,
Yoshiaki Taniyama, MD*,
Takashi Asai, MD*,
Shin Takiuchi, MD*,
Koichi Moriguchi, MD*,
Masashi Ohkuro, MD*,
Norio Komai, MD*,
Kazuo Yamada, MD ,
Nozomu Inamoto, MD*,
Atsuhiro Otsuka, MD ,
Jitsuo Higaki, MD* and
Toshio Ogihara, MD*
* Department of Geriatric Medicine, Osaka University Medical School, Suita, Osaka, Japan
Division of Cardiology, Ibaraki Iseikai Hospital, Ibaraki, Osaka, Japan

View larger version (26K):
[in a new window]
|
Figure 1 Protocol design. i.v. = intravenous; NTG = nitroglycerin.
|
|

View larger version (22K):
[in a new window]
|
Figure 2 Effects of nitroglycerin (NTG) (solid circles, n = 6) and nicorandil (open circles, n=6) on heart rate (HR), mean arterial pressure (MAP), averaged peak (blood) velocity (APV) and coronary blood flow (CBF) in the group with normal coronary arteries. *p < 0.01 vs. NTG.
|
|

View larger version (25K):
[in a new window]
|
Figure 3 Effects of nitroglycerin (NTG) (solid circles, n = 6) and nicorandil (open circles, n = 6) on heart rate (HR), mean arterial pressure (MAP), pulmonary capillary wedge pressure (PCWP), averaged peak (blood) velocity (APV) and coronary blood flow (CBF) in the group with stenotic coronary arteries. *p < 0.01 vs. NTG.
|
|
|